Lactate Dehydrogenase Inhibitors: A Promising Candidate Against Aging And Fibrosis
Our bodies rely on a complex network of chemical reactions to function, and a key player in this network is an enzyme called lactate dehydrogenase (LDH). This enzyme is crucial for how our cells produce energy, particularly through a process called glycolysis, and for maintaining a healthy balance within cells, known as redox homeostasis. However, when LDH activity goes awry, it can contribute to serious health issues like aging and fibrosis, which is the excessive scarring of tissues.
Recent research highlights the exciting prospect of using compounds that block, or inhibit, the activity of LDH. These “LDH inhibitors” work by essentially reprogramming how cells handle their energy and other metabolic processes. By understanding the intricate structure of LDH and its various forms, scientists are developing ways to specifically target its role in aging and fibrosis.
While these inhibitors show great promise, there are challenges to overcome, such as ensuring they act only where needed in the body and avoiding unwanted side effects. To address this, researchers are exploring innovative strategies, including designing “prodrugs” that only become active in specific disease environments, and using advanced delivery systems like nanoparticles to guide these inhibitors precisely to the affected tissues. This approach could pave the way for new treatments to mitigate age-related decline and halt the progression of debilitating fibrotic diseases.
Source: link to paper